Founded in 2024 and based in Stockholm, Haga Bioscience develops spatial RNA analysis technology that enables sensitive, specific detection of single nucleotide variants (SNVs) on RNA directly in situ using new in situ hybridization methods. The company's platform is oriented toward spatial RNA biomarker discovery and clinical translation. Haga has raised approximately USD 2.3M in Seed capital (bringing total funding to about USD 3M including pre-seed) from investors including Almi Invest, Life Science Invest and SU Ventures as well as undisclosed industry veterans, family offices and private investors. The company intends to use the capital to further product development, accelerate commercialization, and expand collaborations with academic and industry partners. Haga will also present its latest advances in translational spatial RNA analysis at the 2026 EACR Congress in Budapest.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2026